In vitro studies on metabolism of salvinorin A

Pharmaceutical Biology

Volumn 47, Issue 11, 2009, Pages 1078-1084

  Kutrzeba, Lukasz M ^a   Karamyan, Vardan T ^a   Speth, Robert C ^a   Williamson, John S ^b   Zjawiony, Jordan K ^a,c  

^a Department of Pharmacognosy ^*

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

In vitro metabolism; Microbial transformation; Salvia divinorum; Salvinorin A

Indexed keywords

ACETIC ACID; SALVINORIN A; SALVINORIN B; TERPENOID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ORGANELLE; CONTROLLED STUDY; DRUG METABOLISM; EX VIVO STUDY; FUNGUS; HYDROLYSIS; IN VITRO STUDY; LIVER; MICROBIAL METABOLISM; NONHUMAN; RAT;

LAMIACEAE; MAMMALIA; MENTHA; RATTUS; SALVIA DIVINORUM;

EID: 70350336634     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880200903002222     Document Type: Article

References (23)

1. Abourashed EA, Clark AM, Huford CD (1999): Microbial models of mammalian metabolism of xenobiotics: An updated review. Curr Med Chem 6: 359-374.
2. Allt G, Lawrenson JG (2000): The blood-nerve barrier: enzymes, transporters and receptors - a comparison with the blood-brain barrier. Brain Res Bull 52: 1-12.
3. Babu KM, McCurdy CR, Boyer EW (2008): Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol 46: 146-152.
4. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WAJ (2008): Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33: 2550-2562.
5. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004): Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203.
6. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989): Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698.
7. El Sayed KA, Hamann MT, Waddling CA, Jensen CL, Sang K, Dunstan CA, Pezzuto JM (1998): Structurally novel bioconversion products of the marine natural product sarcophine effectively inhibit JB6 cell transformation. J Org Chem 63: 7449-7455.
8. Giner JL, Kiemle DJ, Kutrzeba L, Zjawiony JK (2007): Unambiguous NMR spectral assignments of salvinorin A. Magn Reson Chem 45: 351-354.
9. Hanson JR (1992): The microbiological transformation of diterpenoids. Nat Prod Rep 9: 139-151.
10. Mello NK, Negus SS (2000): Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann NY Acad Sci 909: 104-132.
11. Miyazawa M, Kawazoe H, Hyakumachi M (2003): Biopreparation of (-)-(1S,3R,4S,6S)-6-hydroxymenthol and (-)-(1S,3R,4S)-1- hydroxymenthol from 1-menthol by Rhizoctonia solani AG-1-IA and IB. Nat Prod Res 17: 307-311.
12. Orabi KY, Li E, Clark AM, Hufford CD (1999): Microbial transformation of sampangine. J Nat Prod 6: 988-992.
13. Parshikov IA, Miriyala B, Muraleedharan KM, Avery MA, Williamson JS (2006): Microbial transformation of artemisinin to 5-hydroxyartemisinin by Eurotium amstelodami and Aspergillus niger. J Ind Microbiol Biotechnol 33: 349-352.
14. Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R, Torre RD, Zuccaro P (2005): Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 19: 1649-1656.
15. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002): Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci USA 99: 11934-11939.
16. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, Prisinzano TE (2005a): Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58: 208-210.
17. Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ, Murry DJ (2005b): Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B 818: 221-225.
18. Sebek OK (1982): Microbial models of mammalian metabolism. In: Rosazza JP, ed., Microbial Transformation of Bioactive Compounds. Boca Raton, FL, CRC Press, pp. 1-8.
19. Sheffler DJ, Roth BL (2003): Salvinorin A: The "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24: 107-109.
20. Stabler PJ, Holt PJ, Bruce NC (2001): Transformation of 2,2′- bimorphine to the novel compounds 10-α-S-monohydroxy-2,2′- bimorphine and 10,10′-α,α′ -S,S′-dihydroxy-2, 2′-bimorphine by Cylindrocarpon didymum. Appl Environ Microbiol 67: 3716-3719.
21. Valdes LJ, Diaz JL, Paul AG (1983): Ethnopharmacology of Ska Maria Pastora (Salvia divinorum, Epling and Jàtiva-M.). J Ethnopharmacol 7: 287-312.
22. Venisetty RK, Ciddi V (2003): Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr Pharm Biotechnol 4: 153-167.
23. Wang Y, Chen Y, Xu W, Lee DYW, Ma Z, Rawls SM, Cowan A, Liu- Chen, Lee-Yuan (2008): 2-Methoxymethyl-salvinorin B is a potent κ-opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 324:1073-1083.